$1.1 billion. That's what 23 companies have raised to automate cell therapy manufacturing, the most manual and error-prone phase of modern medicine.
A patient's cells are extracted, genetically modified, multiplied, and reinfused. Each step handled by skilled technicians in sterile hoods, one batch at a time. The batch failure rate runs as high as 18%.
A new wave of autonomous platforms combines robotics, AI orchestration, and closed-system design. It targets that fragility. And the Department of Defense is watching closely.
Three forces are converging: private capital ($1.1 billion and counting), regulatory momentum (FDA Advanced Manufacturing Technology designations), and a DARPA push into autonomous science for biological applications.
Cell therapies (CAR-T, TCR, Treg, NK) are among the most potent treatments ever developed. They are also, by any industrial standard, the most expensive and fragile to manufacture. A single dose of a commercial CAR-T therapy costs hundreds of thousands of dollars, and roughly half that cost comes from production, not the drug substance itself. The process is operator-intensive, requires near-sterile conditions, and must be completed without interruption for a patient whose disease may not wait.
Automation has transformed every other sector of precision manufacturing: semiconductors, advanced battery production, even monoclonal antibody synthesis. Cell therapy has resisted that transformation because living cells are not chips. They do not tolerate the same tolerances, the same transfer speeds, or the same environment. A robot that works perfectly in a semiconductor fab would contaminate a cell therapy cleanroom simply by shedding a particle from its own joints.
That technical wall is now falling. A cohort of dedicated automation companies (Cellares, Ori Biotech, Multiply Labs, Streamline Bio, Cellular Origins) has raised $1.1 billion across 34 rounds since 2016, according to a Tracxn report published in June. The bulk of that capital, 81%, is held by two companies: Cellares ($682 million) and Ori Biotech ($281 million). Both now hold the FDA's Advanced Manufacturing Technology (AMT) designation, the only two cell therapy automation platforms to have earned it.
Autonomous cell therapy manufacturing funding
$1.1B raised across 34 rounds since 2016. Cellares alone accounts for $682M. The sector is still early; the top two companies hold 81% of all capital raised. · Tracxn via FiercePharma, June 2026
The platform that fits in a truck
The company is based in South San Francisco. Its Cell Shuttle is an end-to-end automated manufacturing platform roughly the size of a shipping container. It is a self-contained cleanroom on wheels that combines every unit operation required to produce a cell therapy batch: cell selection, activation, genetic modification, expansion, formulation, and quality control.
The platform received FDA AMT designation in April 2025, and the regulatory wins have accelerated since. In January 2026, the agency cleared an IND amendment submitted by Cabaletta Bio for manufacturing of an investigational CAR-T therapy on the Cell Shuttle. It was the first time an end-to-end automated platform was authorized to produce GMP drug product for patient infusion. In July, Cellares announced a collaboration with Sonoma Biotherapeutics to manufacture a CAR-Treg therapy for rheumatoid arthritis, extending the platform into the most sensitive cell therapy modality yet.
It has also joined the FDA's PreCheck program. "What was so compelling for us about the PreCheck program is that it fundamentally changes when the FDA and drug manufacturers engage," said Fabian Gerlinghaus, co-founder and CEO, in an interview with FiercePharma.
How the Cell Shuttle works
1. Input: Patient apheresis material is loaded via sterile tubing.
2. Processing: Cell selection, activation, and genetic modification occur in sequence within closed modules.
3. Expansion: The modified cells are cultured in an integrated bioreactor with real-time sensor monitoring.
4. QC: The Cell Q automated quality control workcell performs in-process and release testing.
5. Output: The final drug product is formulated and cryopreserved in the same closed path.
The entire process reduces manual touchpoints by an estimated 70% compared to conventional CDMO manufacturing. The Cell Shuttle has been evaluated by Bristol Myers Squibb and Cabaletta Bio through Cellares' Technology Adoption Partnership program.
The defence angle that changes the economics
The emerging defence appetite for autonomous biomanufacturing shifts the sector's economics. The Department of Defense has identified domestic biomanufacturing as a critical supply-chain priority. Through the BioMADE Manufacturing Innovation Institute and related programs, DoD has directed approximately $965 million into biomanufacturing since 2020, spanning biomaterials for body armor, explosives, and solvents, with a formal biomanufacturing roadmap expected in 2026.
Then in June, the Defense Advanced Research Projects Agency's Biological Technologies Office issued a Request for Information titled "Advancing Autonomous Science for Biological Applications" (DARPA-SN-26-96), with responses due July 22, 2026. The RFI explicitly seeks input on integrating AI, robotics, and automation into biological discovery and experimentation "in service to national security and public benefit." The document describes a field that "has evolved from small-scale, bespoke systems to large, flexible facilities capable of addressing complex experimental challenges at scale."
The agency's BTO defines three thrust areas: Data Factories, Combat Casualty Care, and Logistics. These map directly onto the capabilities the commercial cell therapy automation companies are building. The "Make" thrust calls for "point-of-need production" and strengthening supply chains for critical commodities. A mobile, autonomous cell therapy manufacturing platform fits that description.
The convergence is not theoretical. Multiply Labs, a San Francisco-based robotics company founded at MIT and Y Combinator, announced a collaboration with AstraZeneca in January 2026 to evaluate GMP-ready robotic systems for commercial-scale cell therapy manufacturing. Its platform uses four robotic arms operating in parallel, trained through imitation learning in NVIDIA Omniverse digital twins, and targets cost reductions exceeding 70% compared with legacy methods. The company already works with Kyverna Therapeutics and Legend Biotech.
DARPA's Autonomous Science RFI closes July 22, 2026. The number and quality of responses will signal the maturity of the ecosystem.
Cellares' Smart Factory in Bridgewater, NJ targets 40,000 batches/year at full capacity. It is the first real-world test of autonomous cell therapy at commercial scale.
The FDA PreCheck program could become the de facto regulatory pathway for automated platforms, creating a first-mover advantage for companies already enrolled.
DoD's biomanufacturing roadmap, expected in late 2026, may designate specific platform technologies for defence contracts.
The rest of the ecosystem
The two market leaders dominate the headlines, but the tail is longer and more varied than the capital concentration suggests. Streamline Bio, a Cambridge-based robotics company, has validated its AI-driven precision robotics platform in live cell therapy production at Made Scientific's Princeton facility and launched an exclusive Early Adopter Program in February 2026. Its modular design integrates with existing cleanroom equipment (Miltenyi CliniMACS Prodigy, G-Rex, LOVO) rather than requiring a full platform swap.
Cellular Origins, a UK-based company, takes a different approach. Its Constellation ecosystem uses mobile robots to connect separate instruments into a closed process, performing sterile fluid transfers between bioreactors, centrifuges, and other devices without redesigning the facility. The company projects a 16-fold reduction in labor and a 50%+ cut in production costs.
At the earlier stage, Cellino Biotech received a $25 million ARPA-H award in 2025 for its autonomous human cell foundry, combining laser technology and machine learning for stem cell-derived therapies. The company raised $80 million in Series A in 2022 from Bayer's Leaps by Bayer, 8VC, and Khosla Ventures, and is working toward the first autonomous GMP-compliant cell foundry.
The diversity of approaches (end-to-end platforms, modular robotic add-ons, mobile instrument connectors) reflects a sector that has not yet standardized on a winning architecture. That is typical for an industry at this stage of capital concentration: the money knows the problem is urgent but is still betting on multiple solutions.
What happens to the cell therapy bottleneck a year from now?
Probability: 65% — Cellares and Ori both hold AMT designation, the PreCheck program compresses the approval timeline, and at least three partnered therapies are targeting Biologics License Applications within 18 months.
✅ Arguments for
It approved 10-20 new cell and gene therapies per year starting in 2025. Each one needs a scalable production solution.
DARPA and DoD funding creates a parallel non-commercial validation path that reduces technology risk.
Confirmation criteria: A BLA filing that explicitly references an automated platform in the manufacturing section.
❌ Arguments against
The capital is concentrated in two companies, and concentration risk is real: if one platform fails a key comparability study, the narrative shifts from "automation is the future" to "automation is not ready."
Regulatory frameworks for autonomous biomanufacturing are still being written. The PreCheck program is voluntary, and its impact on approval timelines is unproven.
Disconfirmation criteria: An automated platform fails a GMP inspection or a partnered therapy misses a manufacturing-related clinical timeline.
Development scenarios
🟢 Optimistic scenario (30%)
Implications: Cell therapy becomes a scalable modality, attracting institutional capital into both platform companies and therapy developers.
🟡 Base-case scenario (50%)
Implications: The thesis is validated but the timeline extends by 2-3 years. Early investors in platform companies see mark-to-market pressure.
🔴 Pessimistic scenario (20%)
Implications: The sector consolidates into a duopoly. Manufacturing cost remains the binding constraint on cell therapy adoption.
As we wrote in July, the intersection of AI and cell therapy is already producing results at the genetic level. AI-designed genetic circuits are rewriting how therapeutic cells are programmed. The manufacturing layer is the next bottleneck to fall. The question is not whether automation reaches cell therapy, but which platforms survive the transition from pilot-scale promise to commercial-scale production.